Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

被引:177
作者
Furumoto, Yasuko [1 ]
Smith, Carolyne K. [2 ]
Blanco, Luz [2 ]
Zhao, Wenpu [2 ]
Brooks, Stephen R. [3 ]
Thacker, Seth G. [4 ]
Zarzour, Abdalrahman [4 ]
Sciume, Giuseppe [5 ]
Tsai, Wanxia L. [1 ]
Trier, Anna M. [1 ]
Nunez, Leti [1 ]
Mast, Laurel [1 ]
Hoffmann, Victoria [6 ]
Remaley, Alan T. [4 ]
O'Shea, John J. [5 ]
Kaplan, Mariana J. [2 ]
Gadina, Massimo [1 ]
机构
[1] NIAMS, Translat Immunol Sect, OST, NIH, Bethesda, MD USA
[2] NIAMS, Syst Autoimmun Branch, NIH, Bethesda, MD USA
[3] NIAMS, Biodata Min & Discovery Sect, OST, NIH, Bethesda, MD USA
[4] NHLBI, Lipoprotein Metab Sect, NIH, Bldg 10, Bethesda, MD 20892 USA
[5] NIAMS, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD USA
[6] NIH, Diagnost & Res Serv Branch, Off Director, Bethesda, MD USA
关键词
PEPTIDYLARGININE DEIMINASE INHIBITION; RHEUMATOID-ARTHRITIS; T-CELLS; PREMATURE ATHEROSCLEROSIS; DISEASE-ACTIVITY; JAK INHIBITORS; I INTERFERON; MRL/LPR MICE; ERYTHEMATOSUS; ALPHA;
D O I
10.1002/art.39818
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Dysregulation of innate and adaptive immune responses contributes to the pathogenesis of systemic lupus erythematosus (SLE) and its associated premature vascular damage. No drug to date targets both systemic inflammatory disease and the cardiovascular complications of SLE. Tofacitinib is a JAK inhibitor that blocks signaling downstream of multiple cytokines implicated in lupus pathogenesis. While clinical trials have shown that tofacitinib exhibits significant clinical efficacy in various autoimmune diseases, its role in SLE and the associated vascular pathology remains to be characterized. Methods. MRL/lpr lupus-prone mice were administered tofacitinib or vehicle by gavage for 6 weeks (therapeutic arm) or 8 weeks (preventive arm). Nephritis, skin inflammation, serum levels of autoantibodies and cytokines, mononuclear cell phenotype and gene expression, neutrophil extracellular traps (NETs) release, endothelium-dependent vasorelaxation, and endothelial differentiation were compared in treated and untreated mice. Results. Treatment with tofacitinib led to significant improvement in measures of disease activity, including nephritis, skin inflammation, and autoantibody production. In addition, tofacitinib treatment reduced serum levels of proinflammatory cytokines and interferon responses in splenocytes and kidney tissue. Tofacitinib also modulated the formation of NETs and significantly increased endothelium-dependent vasorelaxation and endothelial differentiation. The drug was effective in both preventive and therapeutic strategies. Conclusion. Tofacitinib modulates the innate and adaptive immune responses, ameliorates murine lupus, and improves vascular function. These results indicate that JAK inhibitors have the potential to be beneficial in SLE and its associated vascular damage.
引用
收藏
页码:148 / 160
页数:13
相关论文
共 56 条
[1]   SPONTANEOUS MURINE LUPUS-LIKE SYNDROMES - CLINICAL AND IMMUNOPATHOLOGICAL MANIFESTATIONS IN SEVERAL STRAINS [J].
ANDREWS, BS ;
EISENBERG, RA ;
THEOFILOPOULOS, AN ;
IZUI, S ;
WILSON, CB ;
MCCONAHEY, PJ ;
MURPHY, ED ;
ROTHS, JB ;
DIXON, FJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 148 (05) :1198-1215
[2]   Increase in activated CD8+T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus [J].
Blanco, P ;
Pitard, V ;
Viallard, JF ;
Taupin, JL ;
Pellegrin, JL ;
Moreau, JF .
ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :201-211
[3]   Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis [J].
Boers, M ;
Nurmohamed, MT ;
Doelman, CJA ;
Lard, LR ;
Verhoeven, AC ;
Voskuyl, AE ;
Huizinga, TWJ ;
van de Stadt, RJ ;
Dijkmans, BAC ;
van der Linden, S .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :842-845
[4]   IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes [J].
Boggio, Elena ;
Clemente, Nausicaa ;
Mondino, Anna ;
Cappellano, Giuseppe ;
Orilieri, Elisabetta ;
Gigliotti, Casimiro L. ;
Toth, Erika ;
Ramenghi, Ugo ;
Dianzani, Umberto ;
Chiocchetti, Annalisa .
BLOOD, 2014, 123 (08) :1178-1186
[5]   Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon α on lupus endothelial cell progenitors [J].
Cates, Alyssa M. ;
Holden, Victoria I. ;
Myers, Emily M. ;
Smith, Carolyne K. ;
Kaplan, Mariana J. ;
Kahlenberg, J. Michelle .
RHEUMATOLOGY, 2015, 54 (06) :1114-1123
[6]   Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients [J].
Cervera, R ;
Khamashta, MA ;
Font, J ;
Sebastiani, GD ;
Gil, A ;
Lavilla, P ;
Mejía, JC ;
Aydintug, AC ;
Chwalinska-Sadowska, H ;
de Ramón, E ;
Fernández-Nebro, A ;
Galeazzi, M ;
Valen, M ;
Mathieu, A ;
Houssiau, FD ;
Caro, N ;
Alba, P ;
Ramos-Casals, M ;
Ingelmo, M ;
Hughes, GRV .
MEDICINE, 2003, 82 (05) :299-308
[7]   Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor [J].
Changelian, PS ;
Flanagan, ME ;
Ball, DJ ;
Kent, CR ;
Magnuson, KS ;
Martin, WH ;
Rizzuti, BJ ;
Sawyer, PS ;
Perry, BD ;
Brissette, WH ;
McCurdy, SP ;
Kudlacz, EM ;
Conklyn, MJ ;
Elliott, EA ;
Koslov, ER ;
Fisher, MB ;
Strelevitz, TJ ;
Yoon, K ;
Whipple, DA ;
Sun, JM ;
Munchhof, MJ ;
Doty, JL ;
Casavant, JM ;
Blumenkopf, TA ;
Hines, M ;
Brown, MF ;
Lillie, BM ;
Subramanyam, C ;
Shang-Poa, C ;
Milici, AJ ;
Beckius, GE ;
Moyer, JD ;
Su, CY ;
Woodworth, TG ;
Gaweco, AS ;
Beals, CR ;
Littman, BH ;
Fisher, DA ;
Smith, JF ;
Zagouras, P ;
Magna, HA ;
Saltarelli, MJ ;
Johnson, KS ;
Nelms, LF ;
Des Etages, SG ;
Hayes, LS ;
Kawabata, TT ;
Finco-Kent, D ;
Baker, DL ;
Larson, M .
SCIENCE, 2003, 302 (5646) :875-878
[8]   Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib [J].
Charles-Schoeman, Christina ;
Fleischmann, Roy ;
Davignon, Jean ;
Schwartz, Howard ;
Turner, Scott M. ;
Beysen, Carine ;
Milad, Mark ;
Hellerstein, Marc K. ;
Luo, Zhen ;
Kaplan, Irina V. ;
Riese, Richard ;
Zuckerman, Andrea ;
McInnes, Iain B. .
ARTHRITIS & RHEUMATOLOGY, 2015, 67 (03) :616-625
[9]   Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases [J].
Clark, James D. ;
Flanagan, Mark E. ;
Telliez, Jean-Baptiste .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (12) :5023-5038
[10]   LPR AND GLD - SINGLE GENE MODELS OF SYSTEMIC AUTOIMMUNITY AND LYMPHOPROLIFERATIVE DISEASE [J].
COHEN, PL ;
EISENBERG, RA .
ANNUAL REVIEW OF IMMUNOLOGY, 1991, 9 :243-269